STM Journals Peer-reviewed research from Consortium e-Learning Network

Research and Reviews: A Journal of Pharmaceutical Science

Polycystic Ovary syndrome: A disorder of alarming proportion

  1. Irfat Ara
  2. Maqsood Mohd
  3. Mudasir Maqbool
  4. Tawseef Ahmad Hajam

Abstract

Polycystic Ovary Syndrome is one of the most important endocrine disorders that affects women of the reproductive age and may cause serious complications. Insulin resistance plays a key role in the pathophysiology of this syndrome, and this makes the use of oral anti-diabetic drugs most compelling. The majority of studies have shown amelioration of typical symptoms such as hyperandrogenism and cycle irregularities following the use of oral anti-diabetics, and ovulation and pregnancy rates increased. The reproductive and metabolic features of PCOS are sometimes reversible with lifestyle modifications such as weight loss and exercise. Further research is needed to find the exact etiology, methods of prevention and proper management of this endocrine disorder. Though, a plethora of treatment options have arrived for PCOS in recent years the lifestyle modification including a structured meal plan and exercise schedule remains the cornerstone and the most effective modality of treatment till date. As a general rule all other treatment options are added to this depending upon the gravity of the presenting problems. PCOS has achieved an alarming proportion. In this review, we will briefly describe about this multifaceted disorder. Keywords: Polycystic ovary syndrome, insulin resistance, Metformin, exercise, weight reduction.Cite this ArticleIrfat Ara, Maqsood Mohd, Mudasir Maqbool, Tawseef Ahmad Hajam. Polycystic Ovary syndrome: A disorder of alarming proportion. Research & Reviews: A Journal Pharmaceutical Science. 2020; 11(2): 1–7p.

References (30)

  1. Maqbool M., et al. “Polycystic ovarian syndrome- a multifaceted disease: a review”. International Journal of Pharmaceutical Sciences and Research 10.3 (2019): 1072-1079.
  2. Mudasir Maqbool., et al. “Polycysti c in Ovarian Syndrome and Its Various Treatment Strategies”. Indo American Journal of Pharmaceutical Research 5 (2018): 8670-8678.
  3. Maqbool M., et al. “Insulin Resistance and Polycystic ovary Syndrome: A Review”. Journal of Drug Delivery and Therapeutics 9.1 (2019): 433-436.
  4. Brady C., et al. “Polycystic ovary syndrome and its impact on women’s quality of life: More than just an endocrine disorder”. Drug, Healthcare and Patient Safety 1 (2009): 9-15.
  5. Corbould A, Kim YB, Youngren JF, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005 ; 288:E1047-E1054.
  6. Gilling-Smith C, Story H, Rogers V & Franks S Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 1997; 47:93-99
  7. Arlt W, Auchus RJ and Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450cl7 and 3beta -hydroxysteroid dehydrogenase. J Biol Chem 2001; 276:16767-16771.
  8. Zachary T B. World Congress on the Insulin Resistance Syndrome. Insulin resistance mechanisms, the brain, and insulin re sistance in youth and in the polycystic ovary syndrome. Diabetes Care 2009; 33:el24-el30.
  9. Deugarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83:1454–60.
  10. Nestler JE, Jakubowicz DJ, De Vergas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83:2001-5
  11. Pugeat M, Ducluzeau PH. Insulin resistance,polycystic ovary syndrome and metformin. Drugs 1999; 58(1):41–6. Research & Reviews: A Journal of Pharmaceutical Science Volume 11, Issue 2 ISSN: 2229-7006 RRJoPS (2020) 23-27 © STM Journals 2020. All Rights Reserved Page 27
  12. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005; 90(6):3236–42.
  13. Song SH, Rhodes CJ, Veldhuis JD, Butler PC. Diazoxide attenuates glucose -induced defects in first -phase insulin release and pulsatile insulin secretion in human islets. Endocrinol 2003; 144:3399–405.
  14. Panidis D, Skiadopoulos S, Rousso D, Ioannides D, Panidou E. Association of acanthosis nigricans with insulin resistance in polycystic ovary syndrome. Br J Dermatol 1995; 132:936–41.
  15. Adashi EY, Hs ueh AJ, Yen SS. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinol 1981; 108(4):1441-9.
  16. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E et al. Insulin infusion amplifies 1 7 alpha -hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996; 81(3):881-6.
  17. Remsberg KE, Talbott EO, Zborowski JV, Evans RW, McHugh -Pemu K. Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. Fertil Steril 2002; 78:479–86.
  18. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic syndrome who are resistent to clomiphene citrate alone. Fertil Steril 2001; 75:310–15.
  19. Schroder AK, Tauchert S, Ortmann O, Diedrich K, Weiss JM. Insulin resistance in patients with polycystic ovarysyndrome. Ann Med 2004; 36:426–39.
  20. Weiss JM, Polack S, Diedrich K, Ortmann O. Effects of insulin on luteinising hormone and prolactin secretion and calcium signalling in female rat pituitary cells. Arch Gynecol Obstet 2003; 269(1):45–50.
  21. Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril 1993; 59(2):323-31.
  22. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002; 26(7):883-96.
  23. Mohd M, Maqbool M, Dar MA, Mushtaq I, Polycystic Ovary Syndrome, a modern epidemic: An overview, Journal of Drug Delivery and Therapeutics. 2019; 9(3):641-
  24. 24. Maqbool M. “Polycystic Ovary Syndrome; A Burning Issue". Acta Scientific Pharmaceutical Sciences 3.7 (2019): 19.
  25. Maqbool M, Dar MA , Rasool S, Khan M. CURIOUS CASE OF DRUG RESISTANT MALARIA AND ARTEMISININ COMPOUNDS IN THE MODERN ERA. JAPSR (Journal of Applied Pharmaceutical Sciences and Research), 2(2):1-4.
  26. Maqbool M, Dar MA, Rasool S, Bashir R, Khan M; Hepatotoxicity and Hepatoprotective agents: A Mini review; PharmaTutor; 2019; 7(9); 34-40.
  27. Khan M, Maqbool M, Mohammad M, Adesina MA, Fekadu G. AWARENESS ABOUT REPRODUCTIVE HEALTH IN ADOLESCENTS AND YOUTH: A REVIEW. Journal of Applied Pharmaceutical Sciences and Research, 2(3):1-5.
  28. Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J ClinEndocrinolMetab 2005; 90(5):2571–79.
  29. Legro RS, Gnat uk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J ClinEndocrinolMetab 2005; 90(6):3236 –
  30. Polycystic Ovary syndrome: A disorder of alarming proportion Ara et al. RRJoPS (2020) 23-27 © STM Journals 2020. All Rights Reserved Page 28 Cite this Article Irfat Ara, Maqsood Mohd, Mudasir Maqbool, Tawseef Ahmad Haja m. Polycystic Ovary syndrome: A disorder of alarming proportion. Research & Reviews: A Journal Pharmaceutical Science. 2020; 11(2): 23–27p.

You might also find these relevant

Read more of it

Subscribe to one journal or build your own list of several. One invoice, one payment, access for a full year.

Subscribe to journals →

Publish your article

Peer-reviewed journals across every subject, with open access options. Send your manuscript to the right editor today.

Publish with us → Calculate your APC
Support